Market Overview

Mylan Launches Generic Version of Qualaquin Caps

Share:
Related MYL
Analyst Knocks High-Profile Biotech Merger Battle; Opportunities Elsewhere
Mylan Sends Letter to Teva CEO
Wall Street Breakfast: Investors Await ECB Decision And Conference (Seeking Alpha)

Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Quinine Sulfate Capsules USP, 324 mg. This product is the generic version of Mutual Pharmaceutical Company, Inc.'s Qualaquin^® Capsules, and is an antimalarial drug indicated only for treatment of uncomplicated Plasmodium falciparum malaria.(1)

Quinine Sulfate Capsules USP, 324 mg, had U.S. sales of approximately $31.9 million for the 12 months ending Sept. 30, 2012, according to IMS Health. Mylan has begun shipping this product.

Posted-In: News

 

Related Articles (MYL)

Around the Web, We're Loving...